NCT02955940Active, not recruitingPhase 2
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 3 Nov 2016
- Start date
- 30 Nov 2016
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Incyte Corporation
- NCT number
- NCT02955940
- EU CT number
- 2023-507225-42-00
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 10
- From 30 Nov 2016 to the primary completion date, 30 Sept 2027
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.
Other
- Has been permanently discontinued from study treatment in the parent study for any reason.
Who the study is looking for
- Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated.
- Currently tolerating treatment in the parent protocol.
- Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator.
- Have at least stable disease, as determined by the investigator.
- Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie Coordinator of this site? Confirm its status | Cracow | Poland | Recruiting |
| Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie Coordinator of this site? Confirm its status | Lublin | Poland | Recruiting |
| Instytut Hematologii I Transfuzjologii Coordinator of this site? Confirm its status | Warsaw | Poland | Recruiting |
| New York Oncology Hematology Pc. Coordinator of this site? Confirm its status | Clifton Park | United States | Unknown status |
| University of Texas M.D. Anderson Cancer Center Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
| University of Louisville Coordinator of this site? Confirm its status | Louisville | United States | Unknown status |
| Tennessee Oncology Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| UCLA Healthcare Hematology-Oncology Coordinator of this site? Confirm its status | Santa Monica | United States | Unknown status |
| Renovatio Clinical Consultants Llc Coordinator of this site? Confirm its status | The Woodlands | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.